Outcomes after TIPS in patients with cirrhosis and sarcopenia: A systematic review and meta-analysis Maria de Brito Nunes, Maria Gabriela Delgado, Jaume Bosch, Annalisa Berzigotti JHEP Reports.2026; 8(2): 101699. CrossRef
CIRROSE HEPÁTICA EM HOMENS ADULTOS: UMA REVISÃO INTEGRATIVA Matheus Cavalcanti Saraiva, Thales Gabriel de Azevedo Costa, Maria Auxiliadora Menezes De Souza, Luisa Margareth Carneiro Da Silva, Ana Lúcia Rocha Faillace, Ana Lúcia da Silva Resende ARACÊ .2026; 8(3): e12482. CrossRef
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrh Georg Semmler, Lorenz Balcar, Mattias Mandorfer Clinical and Molecular Hepatology.2025; 31(2): e224. CrossRef
Advancing our understanding of recompensated cirrhosis - the new “holy grail” of decompensated cirrhosis Thomas Reiberger, Benjamin Maasoumy Journal of Hepatology.2025; 83(3): 615. CrossRef
Woo Jin Chung, M.D., Byung Kuk Jang, M.D., Kyung Sik Park, M.D., Kwang Bum Cho, M.D.,
Jae Seok Hwang, M.D., Sung Hun Ahn, M.D., Yong Hoon Kim, M.D.1, Young Hwan Kim, M.D.2
and Yong Ju Kim, M.D.3
Background/Aims Transjugular Intrahepatic Portosystemic Shunt (TIPS) is commonly used in patients
with variceal bleeding. However, this procedure is contraindicated in hepatocellular carcinoma patients with
portal vein thrombosis. This study was done to evaluate the effect of TIPS in those patients with variceal
bleeding. Methods: Between 1997 and 2004, six hepatocellular carcinoma (HCC) patients with portal vein
thrombosis were enrolled in this study due to their variceal bleeding. All the patients underwent TIPS
placement to treat the variceal bleeding that had not responded to endoscopic treatment. Effective shunt
creation was assessed by the decrease of the portal pressure gradient (less than 12 mmHg) or if good
patency and flow were seen on a doppler examination. Results: Shunts were successfully created in all the
patients and the bleeding was immediately controlled in the active bleeding cases. The bleeding was caused by
esophageal varices in one patient and, by gastric varices in five patients. The HCC types were diffuse or
massive in five patients, and a single nodule was present in one patient. All the patients had portal vein
thrombosis. Rebleeding was noted in two patients at 10 days and 3 months, respectively, due to the shunt
occlusion. Hepatic encephalopathy was noted in two patients. The causes of death were hepatorenal syndrome
after 2 weeks in one patient, bleeding due to portal hypertensive gastropathy after 3 weeks in another, and
cancer progression after 4 months in third patient. Conclusions: For HCC patients with portal vein thrombosis,
TIPS can be an effective treatment modality if uncontrolled variceal bleeding presents when using endoscopic
hemostasis or pharmacologic therapy. However, further studies are needed. (Korean J Hepatol 2005;11:
157-163)
Portal vein occlusion has previously been considered as a contraindication for TIPS placement. Several recent reports have suggested that placement of TIPS may be effective in patients with occluded portal veins to embolize varices and recanalize venous obstruction. We experienced a case of variceal bleeding associated with portal vein thrombosis who was success- fully treated with TIPS placement. So we report the case with a brief review of literatures.
Refractory hepatic hydrothorax has been treated by conservative methods: salt and water restriction, diuretics, thoracentesis, thoracostomy, and pleurodesis. The results, however, havebeen disappointing. Recently, TIPS has emerged as a new method for refractory hepatic hydrothorax, but it may lead to fatal complications. We report a case of refractory hepatic hydrothorax that was not treated by TIPS despite of successful control of ascitest. (Korean J Hepatol 2002;8:327-330)